Business Context and Reporting Period
Company: STAAR Surgical Company
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended March 30, 2001
Business Overview: The Company develops, manufactures, and markets surgical instruments and devices, primarily intraocular lenses (IOLs) and phacoemulsification systems. Operations include significant international sales, primarily to Europe.
Key Financial Metrics
| Metric | Q1 2001 | Q1 2000 |
|---|---|---|
| Total Revenues | $13.0 million | $14.1 million |
| Gross Profit | $7.8 million (60.2% margin) | $8.7 million (61.2% margin) |
| Operating Income (Loss) | ($0.3 million) | $0.3 million |
| Net Income (Loss) | ($0.2 million) | $0.3 million |
| Cash and Cash Equivalents | $4.0 million | $3.4 million (end of period) |
| Notes Payable | $8.5 million | N/A (Balance sheet comparison) |
| Net Working Capital | $24.7 million | $24.3 million (Dec 29, 2000) |
Cash Flow: Net cash used in operating activities was $2.3 million. Net cash provided by financing activities was $0.5 million, primarily from increased borrowings. Investing activities provided $15,000 in net cash.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 8.0% to $13.0 million. Management attributes this to discontinued operations reported in Q1 2000 and unfavorable foreign exchange rates. Excluding these factors, revenues were essentially flat.
- Profitability Shift: The Company reported a net loss of $230,000 compared to a net income of $264,000 in the prior year. Operating income turned negative ($346,000 loss) from a positive $339,000.
- Expense Mix: Marketing and selling expenses increased as a percentage of revenue to 39.2% (from 34.5%) due to lower revenues and higher commissions. Research and development expenses decreased 26.3% to $818,000.
- Inventory Build-up: Inventories increased by $1.7 million to $22.5 million, driven by contractual commitments for Sonic WAVE units, Collamer IOLs, and Visacryl lenses.
Outlook, Risks, and Contingencies
- Covenant Waiver: The Company's primary credit facility ($7.0 million line of credit) requires positive net income after taxes. The Company was not in compliance as of March 30, 2001, but obtained a waiver from the lender. The note is due July 2, 2001.
- Financing Needs: Management is seeking alternative financing to pay down or replace the current credit facility. There is no assurance of success or favorable terms.
- Legal Proceedings:
- Canon Dispute: Ongoing arbitration with Japanese joint venture partners (Canon, Inc. and Canon Sales Co., Inc.) regarding alleged breaches of joint venture and license agreements. Canon seeks unspecified damages; STAAR seeks an accounting of profits and transfer of interest.
- Former CEO Litigation: Lawsuits filed by and against former President/CEO John R. Wolf regarding wrongful termination, stock options, and loans made to him.
- Forward-Looking Statements: Management expects to be profitable in the future and believes current cash and credit facilities are adequate to fund operations, subject to risks including competitive pressures and economic conditions.
Investor Verification Checklist
- Verify the status of the waiver obtained from the domestic lender and the timeline for securing alternative financing before the July 2, 2001 maturity date.
- Monitor the resolution of the arbitration with Canon, Inc., as the outcome could impact future revenue streams or result in significant liabilities.
- Assess the impact of the inventory buildup ($1.7 million increase) on future cash flow and potential write-downs if demand does not materialize.
- Review the progress of the restructuring plan initiated in 2000, specifically the remaining accrued costs of $1.7 million.
- Confirm the stability of the European market, which accounts for the majority of foreign sales, given the noted impact of exchange rates.